Lung Neuroendocrine Neoplasm
Associated Genetic Biomarkers
NCI Definition: A low, intermediate, or high grade malignant neoplasm with neuroendocrine differentiation that arises from the lung. This category includes typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma, and combined carcinoma. 
Lung neuroendocrine neoplasms most frequently harbor alterations in TP53, RB1, KMT2D, CREBBP, and NOTCH1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, RB1 Mutation, and TP53 Exon 5 Mutation are the most common alterations in lung neuroendocrine neoplasm .
There are 14 clinical trials for lung neuroendocrine neoplasm, of which 10 are open and 4 are completed or closed. Of the trials that contain lung neuroendocrine neoplasm as an inclusion criterion, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (0 open).
SSTR2, SSTR1, and SSTR3 are the most frequent gene inclusion criteria for lung neuroendocrine neoplasm clinical trials .
Nivolumab, 177lu-dotatoc, and 177lu-opsc001 are the most common interventions in lung neuroendocrine neoplasm clinical trials.
Significant Genes in Lung Neuroendocrine Neoplasm
EGFR is altered in 7.11% of lung neuroendocrine neoplasm patients .
EGFR is an inclusion eligibility criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.